Erlotinib induces cell cycle arrest and apoptosis in hepatocellular cancer cells and enhances chemosensitivity towards cytostatics.
about
EGFR Signaling in Liver DiseasesNanoparticles for targeted delivery of therapeutics and small interfering RNAs in hepatocellular carcinomaOncolytic Virus-Based Immunotherapies for Hepatocellular Carcinoma.Epidermal Growth Factor Receptor Cell Proliferation Signaling PathwaysExploiting novel molecular targets in gastrointestinal cancers.Dual induction of caspase 3- and transglutaminase-dependent apoptosis by acyclic retinoid in hepatocellular carcinoma cells.Could HBx protein expression affect signal pathway inhibition by gefitinib or selumetinib, a MEK inhibitor, in hepatocellular carcinoma cell lines?Novel therapeutic strategies for targeting liver cancer stem cells.Enhanced anti-angiogenic effect of E7820 in combination with erlotinib in epidermal growth factor receptor-tyrosine kinase inhibitor-resistant non-small-cell lung cancer xenograft models.Targeted therapy in hepatocellular carcinomaChemotherapy and target therapy for hepatocellular carcinoma: New advances and challenges.Erlotinib-mediated inhibition of EGFR signaling induces metabolic oxidative stress through NOX4.Oridonin-induced apoptosis in SW620 human colorectal adenocarcinoma cells.Induction of apoptosis in the SW620 colon carcinoma cell line by triterpene-enriched extracts from Ganoderma lucidum through activation of caspase-3.Molecular biology of epidermal growth factor receptor inhibition for cancer therapy.Mechanisms of doxorubicin resistance in hepatocellular carcinomaSynergistic inhibition of head and neck tumor growth by green tea (-)-epigallocatechin-3-gallate and EGFR tyrosine kinase inhibitor.Genetic diversity of hepatocellular carcinomas and its potential impact on targeted therapies.Evolving therapies in the treatment of hepatocellular carcinomaCyclooxygenase-2 prevents fas-induced liver injury through up-regulation of epidermal growth factor receptor.Combination of ruthenium(II)-arene complex [Ru(η6-p-cymene)Cl2(pta)] (RAPTA-C) and the epidermal growth factor receptor inhibitor erlotinib results in efficient angiostatic and antitumor activity.Novel inhibitors in development for hepatocellular carcinoma.Pathways and targets in hepatocellular carcinoma.Epidermal Growth Factor Receptor (EGFR) Crosstalks in Liver Cancer.Novel thiazole derivatives: a patent review (2008 - 2012; Part 1).In vitro prediction of the efficacy of molecularly targeted cancer therapy by Raman spectral imaging.Synthesis, molecular docking and biological evaluation of glycyrrhizin analogs as anticancer agents targeting EGFR.Label-free imaging of drug distribution and metabolism in colon cancer cells by Raman microscopy.Combination of cetuximab and rapamycin enhances the therapeutic efficacy in hepatocellular carcinoma.EGFR activation is a potential determinant of primary resistance of hepatocellular carcinoma cells to sorafenib.Antitumor effects of chi-shen extract from Salvia miltiorrhiza and Paeoniae radix on human hepatocellular carcinoma cells.Signaling pathways involved in the inhibition of epidermal growth factor receptor by erlotinib in hepatocellular cancer.Interferon-α reduces the gefitinib sensitivity of human non-small cell lung cancer.Oxidative stress mediates an increased formation of vascular endothelial growth factor in human hepatocarcinoma cells exposed to erlotinib.Impact of epidermal growth factor receptor protein and gene alteration on Taiwanese hepatocellular carcinomas.Hepatocellular carcinoma treated with anti-epidermal growth factor receptor antibody nimotuzumab: A case reportHepatocellular Carcinoma: Past and Future of Molecular Target Therapy.Targeted medical therapy of biliary tract cancer: recent advances and future perspectives.Treatment of gastrointestinal neuroendocrine tumors with inhibitors of growth factor receptors and their signaling pathways: recent advances and future perspectives.Growth factor receptors and related signalling pathways as targets for novel treatment strategies of hepatocellular cancer.
P2860
Q26771265-44AD8F1E-5F67-414A-8F38-DA9E48BF0047Q26823523-51506217-6361-437F-AFE0-8E7C1AC23677Q33635033-F5901918-6CF6-4E46-B587-0CA2E4D28287Q33737298-49423302-1DF0-42D3-AC63-C4CC309EDA51Q34382777-57AC798D-92AE-44F8-AA0D-C98E6A349E1CQ34506882-EAC9EB69-95C9-44BC-A244-98E3E1C0745EQ34539948-0C4EC5C3-22BA-4AE7-8220-9997ED938F84Q34940971-FA7AEE28-64C6-43A3-A358-37B3C5668C41Q35051626-B9566CBE-9012-490F-B873-93168A8835B8Q35207561-269B9F6D-A88B-4B5A-83C8-8F7C28B42B80Q35501246-6BDE707B-6E8A-43A9-B508-2DFF5226FDA0Q35553145-9B10B8EA-E15A-4D69-9325-92FFB56105FDQ36121430-7FB979E9-3FA5-469F-A974-958A468889E8Q36135366-27A64310-8E3A-47CF-950C-9651167E5E1BQ36481002-00058889-8042-4DC5-8ED8-FE5B1580AC86Q36687760-77DA815A-FF5C-4BC9-8EA9-055003DC114BQ36914407-F8C2A7E5-AB8A-4A29-BFE7-8A3F2AC103C9Q36918126-3EB18F5F-C693-4276-A3D8-CF5F31C7DA4FQ37290714-F282E8CE-0859-4149-A216-7CC4E2DE70E5Q37378968-01C1E67F-4935-4CD1-A912-3A117C50001FQ37657640-56719A8F-C93B-4C79-93A1-EB6DC1FB77A0Q37725994-D8A3D0A5-5611-4D10-AF89-C94B8D900F3BQ38062022-48A7B2F1-6530-49FE-A684-EC74E17A687AQ38161361-287616E8-5BF6-4818-9F65-F2A1FEE623D4Q38161545-59DA0C22-4455-4F3D-9891-4CBC10203B40Q38853649-FE0ADD95-373D-4979-8BAD-774AB1657CD7Q38992642-CC58B72F-BD91-48F9-BED4-EEC68415A360Q39034201-69F6274A-FE12-4135-8072-99FBC0241F90Q39044822-381F8460-72FC-4CF9-8478-B0C837013EEEQ39362619-B3336F93-E48A-424C-8126-55BDB85CCF83Q40104999-CEE9B2C9-C782-406E-88BA-9DC83E76EDD9Q40238825-ACBD316A-94DA-4548-BF1A-486A56C69686Q41148890-F4A829FD-E33B-4932-AFEA-3ACBEE45D584Q41342988-72F0DE21-664D-44CC-967E-C7472E9B063CQ41434771-05D6634C-B02D-4080-BEE0-AEC756E14109Q41952696-C2DA5C15-9117-404C-AA14-27705BC40DC9Q42053469-CCDF66C2-EF2A-4CAE-9F1E-C00815931AB2Q42635172-2746B053-EA2F-4397-9738-8D9AF4E59031Q43097453-13688BD7-8055-460D-BFB4-A11F9E1576B7Q43141124-EDD0EA7E-B941-41BE-8AE6-54F4A265EA5D
P2860
Erlotinib induces cell cycle arrest and apoptosis in hepatocellular cancer cells and enhances chemosensitivity towards cytostatics.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Erlotinib induces cell cycle a ...... nsitivity towards cytostatics.
@en
type
label
Erlotinib induces cell cycle a ...... nsitivity towards cytostatics.
@en
prefLabel
Erlotinib induces cell cycle a ...... nsitivity towards cytostatics.
@en
P2093
P1476
Erlotinib induces cell cycle a ...... nsitivity towards cytostatics.
@en
P2093
Alexander Huether
Andreas P Sutter
Detlef Schuppan
Hans Scherübl
Michael Höpfner
P304
P356
10.1016/J.JHEP.2005.02.040
P577
2005-10-01T00:00:00Z